Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Scientific Reports 9(1):15582, 2019
The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach
Molecular Metabolism 21:36-50, 2019
Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice
Biomedicine & Pharmacotherapy 109:167-173, 2019
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice
Physiology and Behavior 192:72-81, 2018
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Journal of Peptide Science 23(12):845–854, 2017
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues
Journal of Medicinal Chemistry 60(17):7434–7446, 2017
A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
ACS Chemical Biology 12(8):2107–2116, 2017
Neoglycolipids for prolonging the effects of peptides: Self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy
Molecular Pharmacology 14(1):193–205, 2017